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BACKGROUND. In spite of intensive efforts, understanding of the genetic aspects of familial
prostate cancer (PC) remains largely incomplete. In apreviousmicrosatellite-based linkage scan
of 1,233 PC families, we identiﬁed suggestive evidence for linkage (i.e., LOD 1.86) at 5q12,
15q11, 17q21, 22q12, and two loci on 8p,with additional regions implicated in subsets of families
deﬁned by age at diagnosis, disease aggressiveness, or number of affected members.
METHODS. In an attempt to replicate these ﬁndings and increase linkage resolution, we used
the Illumina 6000 SNP linkage panel to perform a genome-wide linkage scan of an independent
set of 762 multiplex PC families, collected by 11 International Consortium for Prostate Cancer
Genetics (ICPCG) groups.
RESULTS. Of the regions identiﬁed previously, modest evidence of replication was observed
only on the short arm of chromosome 8, where HLOD scores of 1.63 and 3.60 were observed in
the complete set of families and families with young average age at diagnosis, respectively. The
most signiﬁcant linkage signals found in the complete set of families were observed across a
broad, 37 cM interval on 4q13–25, with LOD scores ranging from 2.02 to 2.62, increasing to 4.50
in families with older average age at diagnosis. In families with multiple cases presenting with
more aggressive disease, LODscores over 3.0were observed at 8q24 in the vicinity of previously
identiﬁed common PC risk variants, as well asMYC, an important gene in PC biology.
CONCLUSIONS. These results will be useful in prioritizing future susceptibility gene
discovery efforts in this common cancer. Prostate 72: 410–426, 2012. # 2011WileyPeriodicals, Inc.
KEY WORDS: prostate cancer; hereditary; susceptibility; 8q24;
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INTRODUCTION
The recent discoveries of multiple SNPs across the
genome as common, reproducible genetic risk factors
for prostate cancer (PC) have been impressive. Over 30
common sequence variants have now been conﬁrmed
to be associated with PC risk, emphasizing the
polygenic nature of inherited susceptibility for this
disease [1]. In spite of the substantial progress in this
area, current estimates suggest that the identiﬁed loci
do not explain themajority of the excess risk associated
with PC family history [1], one of themost reproducible
risk factors for PC [2,3].
Attempts to map PC susceptibility genes by linkage
analysis of individual family collections have yielded
few reproducible leads despite numerous genome-
wide scans, most likely due to genetic and disease
heterogeneity [4–6]. In an effort to address this
question more effectively, we previously carried out a
large linkage study that included 1,233 PC families
collected by members of the International Consortium
for Prostate Cancer Genetics (ICPCG) [7]. This study
provided strong evidence that one or a fewmajor genes
cannot account for the majority of disease in PC
families. At the same time, a number of loci demon-
strated suggestive linkage signals, consistent with a
complex genetic etiology for this disease. To extend
these studies using a higher resolution marker set, and
to assess which of these linkage signals might warrant
additional investigation, in this report we describe
a second combined linkage analysis with 6,000 SNPs to
interrogate an independent set of 762 families collected
by the ICPCG.
RESULTS
Study Population: 762 ProstateCancer Families
Table I summarizes the characteristics of the 762 PC
families from the 11 ICPCGgroups participating in this
analysis. Fifty-three percent of families had amean age
at diagnosis of <65 years, and 21% had four or more
affected family members. Most of the families (65%)
were collected in Europe or Australia, with the
remainder collected in the US. The current analysis
was restricted toCaucasian families; analysis of linkage
results from African American pedigrees collected by
members of the ICPCG will be described in a separate
report.
SNPScan Linkage Results
Shown in Figure 1 andTable II are the linkage results
for the entire set of 762 families using dominant (dom),
recessive (rec), and nonparametric (KCLOD or asm)
linkage models. The strongest evidence of linkage in
the complete set of families is located in a broad region
with multiple peaks on the proximal and mid-q arm
of chromosome 4. A maximum HLOD¼ 2.62 was
observed under a recessive model at 4q22 at 97 cM,
along with several other peaks over 1.86 between 74
and 115 cM, 4q13–25.Anexamination of LODscores by
individual family collection indicates that six of the
seven largest family collections had scores over 0.9 in
the 12 cM interval between 83 and 102 cM on this
chromosome, using either a recessive or asm model
(Table III).
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TABLE I. Characteristics of 762 ICPCGFamilies
ICPCG member
Mean age at
diagnosis Number of affected members
Families
with
aggressive
PC Total
<65 >65 2 3 4 >5 Families
Affected
individuals
Nonaffected
individuals
ACTANE 108 71 89 72 13 5 150 179 380 83
Univ Tampere 24 33 16 32 6 3 42 57 144 159
CeRePP 87 87 110 49 11 4 63 174 385 73
FHCRC 3 10 12 1 0 0 3 13 27 0
JHU 19 5 2 10 5 7 10 24 78 24
Mayo Clinic 6 5 2 6 2 1 0 11 29 10
Univ Michigan 88 43 55 58 12 6 0 131 344 0
Northwestern Univ 12 2 11 3 0 0 0 14 29 6
Karolinska Inst 11 24 7 19 7 2 4 35 88 25
Univ Ulm 34 16 17 28 5 0 17 50 114 21
Univ Utah 13 61 0 0 55 19 59 74 143 268
Total 405 357 321 278 116 47 348 762 1,761 699
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One other region, 18q11, reached the threshold for
suggestive evidence of linkage: rec HLOD¼ 1.93 at
43 cM. Including results from all three linkage models,
LOD scores over 1.5 were observed at 8p11 (59 cM),
8q24 (142 cM), 11p15 (7 cM), 12q23 (114 cM), 16q21
(81 cM), and multiple positions on both arms of
chromosome 2 (2p16, 77 cM; 2p11, 108 cM; 2q14,
131 cM; and 2q35, 216 cM) (Table II).
Linkage Signals in Subsets of Families
To explore variables that might impact the linkage
results, we analyzed subsets of families characterized
by young or old average age at diagnosis (<65 vs. 65 or
older), ﬁve or more affected individuals, or multiple
members affected with more aggressive disease. For
the 405 families with young age of diagnosis, the most
signiﬁcant evidence for linkage was observed on 8p11
at 59 cM (dom HLOD¼ 3.60 vs. 1.63 at this same
position in all families). Two other regions showing
suggestive linkage in this family subset were observed,
at 3p24 (asm LOD¼ 2.05 at 35 cM), and 1q44 (asm
LOD¼ 1.95 at 269 cM) (Fig. 2; Table IV).
In families with an average age at diagnosis of 65 or
greater (n¼ 357), LOD scores over 1.86 are seen in a
broad region spanning the centromere of chromosome
4 (51–122 cM), which overlaps with the strongest
region of linkage observed in the complete set of
families. The peak for this subset analysis was at 95 cM,
4q22, with a rec HLOD¼ 4.50. Other positions
with LOD scores over 1.86 in this subset of families
were observed on chromosomes 12, 13, and 18 (dom
HLOD¼ 3.14, rec HLOD¼ 2.23 and 1.91 at 113, 15,
and 43 cM, respectively) (Fig. 3, Table IV).
The strongest linkage signals in families with more
aggressive disease were seen on chromosome 8 where
LOD scores reached over 3.0 across a 14 cM interval at
8q24 (126–140 cM, high score 3.17 at 132 cM, dom
model). Four other regions were of interest in this
group: 1q43 (dom HLOD¼ 2.11 at 255 cM), 2q35 (asm
LOD¼ 2.24 at 218 cM), and 4q32 (dom HLOD¼ 1.94 at
149 cM), 12q24 (dom HLOD¼ 2.23 at 146 cM) (Fig. 4,
Table IV).
In families with ﬁve or more affected individuals,
suggestive evidence of linkage was observed at
three regions: 13q34 (asm LOD¼ 2.46, 128 cM), 15q14
The Prostate
Fig. 1. a: Plot of LOD scores for all families by chromosome. b: Chromosomes with LOD scores>1.86 in all families. c: Chromosomes
withLODScores>1.5 inall families.
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(40 cM, dom HLOD¼ 2.0), and 16p12.1 (rec HLOD¼
2.0, 48 cM) (Fig. 5; Table IV). On chromosome 21, an
HLOD of 1.78 was observed at 45 cM, in the vicinity of
the ERG and TMPRSS2 genes, in this family subset
(Fig. 5c).
Comparison of Two Linkage Scans
in ICPCGFamilies
To search for reproducible linkage signals, we
compared the results of this SNP linkage scan (des-
ignated here SNP scan) with our previous scan of 1,233
families using microsatellite markers (MS scan) [7]. Of
the six regions of suggestive linkage found in the MS
scan, none were supported by LOD scores reaching the
threshold for suggestive linkage, that is, 1.86, in the
SNP scan. However, more modest evidence of repli-
cation was observed on the proximal short arm of
chromosome 8. In the SNP scan, an HLOD of 1.63 was
observed at 8p11 (59 cM) under a dominant model. In
the MS scan, two signals were observed on 8p, one at
60 cM (1.94) and one at 46 cM (1.97), under recessive
and dominant models, respectively. For the remaining
four regions of suggestive linkage found in our ﬁrst
scan, at 5q12, 15q11, 17q21, and 22q12, little or no
evidence for linkage was seen in the SNP scan (LOD
scores< 0.4).
Similarly, for all regions reaching LOD scores of 1.5
or greater in the complete set of families analyzed in the
SNP scan, including the multiple loci on chromosomes
2 and 4, 8p11, 11p15, 12q23, 16q21, and 18q11, the
highest score observed in the MS scan was 0.53 at
133 cM on chromosome 2.
Comparison of Two Linkage Scans
in Subsets of Families
In families with a young age at diagnosis, dom
HLOD scores 1.86were observed on 3p in both scans,
although the peak locations differed by over 20 cM
(35 cM in SNP scan and 57 cM in MS scan). When
comparing regions of linkage in the scans of families
with ﬁve or more affected members, peaks over 1.86
were observed within 15 cM of each other on 16p12
(at 34 cM inMS scan and 49 cM in SNP scan) (asm LOD
2.04 and 2.14, respectively).
Of the three regions reaching suggestive linkage
(6p22, 11q14, and 20q11) in our previous MS scan of
families with aggressive disease, one region, 11q14
provided some evidence of an overlapping signal in the
SNP scan with a rec HLOD score of 0.8 at 100 cM. Also
in this group of families, coinciding linkage signals
occurred at 8q24, where dom HLOD scores of 1.17 and
3.05were observed in the samepositions (137 cM) in the
MS and SNP scans, respectively.
DISCUSSION
In this report, we describe a genome-wide linkage
study of 762 families collected by members of the
ICPCG. This is the second largest collection of PC
The Prostate
Fig. 1. (Continued )
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TABLE II. LODScore SummaryAll Families (n¼ 762)*
Chr Pos (cM) LODa Model Region SNP Pos (bp)b
2 77 1.60 rec 2p16.1 rs1961245 54,947,346
2 108 1.66 rec 2p11.2 rs11395 86,219,118
2 131 1.85 asm 2q14.2 rs280192 121,453,668
2 216 1.66 asm 2q35 rs750365 218,099,708
4 77 2.02 rec 4q13.1 rs1489572 63,718,108
4 93 2.26 asm 4q21.23 rs1383972 86,603,353
4 98 2.62 rec 4q22.1 rs729685 90,654,297
4 102 2.58 rec 4q22.2 rs183993 95,349,048
4 114 2.58 rec 4q25 rs1879053 111,616,397
8 59 1.63 dom 8p11.21 rs868586 40,824,008
8 142 1.63 asm 8q24.22 rs1062064 133,081,398
11 7 1.53 dom 11p15.4 rs2231963 4,581,596
12 114 1.62 asm 12q23.2 rs1544921 100,635,304
16 81 1.50 rec 16q21 rs1027277 61,242,497
18 43 1.93 rec 18q11.2 rs948384 18,260,958
*All scores> 1.5.
aHLOD scores listed for dom and rec models.
bhg18 (http://genome.ucsc.edu/).
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families analyzed to date to assess linkage across the
genome. A primary rationale behind this study was to
determine whether linkage signals observed in an
earlier microsatellite linkage scan of 1,233 families
could be replicated, as a means to identify loci
warranting further study.
Of the six regions of suggestive linkage observed
in the previous MS scan of 1,233 PC families [7], one
region, 8p11, attained a LOD score over 1.5 in the
present SNP scan. In addition, overlapping linkage
signals in the two scans provided some evidence of
replication in deﬁned subsets of families analyzed.
The Prostate
TABLE III. LODScoresonChromosome 4
Group LODa Pos (cM) Model # Families
Actane 1.20 98 asm 179
Univ Tampere 1.36 83 rec 57
CeRePP 1.54 83 rec 174
Karolinska Inst 1.71 102 rec 35
Univ Ulm 0.94 102 rec 50
Univ Utah 1.00 93 rec 74
MAYO Clinic 0.36 83 rec 11
FHCRC 0.00 83–102 rec 13
JHU 0.33 83 rec 24
Univ Michigan 0.00 83–102 rec 131
NW Univ 0.09 102 asm 14
aHLOD scores listed for rec model.
Fig. 2. a: Plot of LODScores for familieswith average age atdiagnosis under 65.b: Chromosomeswith LOD scores1.86 in familieswith
youngageatdiagnosis (<65).
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Both families with young age at diagnosis and families
with ﬁve or more affected individuals had moderate
linkage signals at 3p24 and 16p12, respectively, in both
scans. In addition, the subset of families with clinically
aggressive disease showed linkage to 8q24 in both
scans. Thus, while overall replication of previous
linkage peaks was quite limited, several loci, partic-
ularly on chromosome 8, showed consistent linkage
signals in two large, independent collections of PC
families.
Chromosome 8 has long been suggested to harbor
both prostate tumor suppressor gene(s) and onco-
gene(s) due to the frequent copy number alterations
(deletions of 8p and gains of 8q, respectively) occurring
somatically in specimens of prostate tumor tissue
[8–10], reviewed in [11,12]. At the germline level,
linkage at 8phas beenobserved inPC family collections
from Japan, Sweden, Germany, and the US [13–17],
although in majority of these studies the signals
observed were more telomeric than the one observed
here. In addition, a large case–control study conducted
by PRACTICAL found two SNPs at 8p21, nearNKX3.1,
to be associated with PC risk [18].
The 8q24 locus been extensively analyzed byGWAS,
with ﬁve or more regions reproducibly shown to be
associated with PC risk [19–21]. Associations of
inherited PC risk and this region were ﬁrst identiﬁed
through a ﬁne-mapping study of a linkage peak
observed in a genome-wide scan of Icelandic PC
families [22]. Linkage to this region was also reported
by Camp et al. [23] in extended PC families from Utah.
In future studies, it will be of interest to determine
whether any of the susceptibility loci identiﬁed in the
original study and the association studies since,
contribute to the linkage signals observed here. A gene
of particular interest for PC,MYC, lies in the region of
linkage observed in this study in families with more
aggressive disease. Previous studies have demon-
strated the common up-regulation of this gene early
in human prostate carcinogenesis [24][25], ampliﬁca-
tion of the gene in advanced PC [26][27], and the ability
of prostate-speciﬁc expression of this gene to induce PC
in animal models [28][29]. Such studies, together with
recent work demonstrating interactions between risk
loci and MYC regulatory elements have led to the
hypothesis that the 8q24 risk alleles that have been
identiﬁed to date modify PC risk mechanistically by
alteringMYC regulation and expression [30–34].
In the complete family collection, the strongest
linkage signals in this study were observed on the
proximal and mid q arm of chromosome 4. One
important aspect of this signal is the contributions
provided by the multiple different family collections.
Interestingly, six of the seven largest family collections
(ranging from 35 to 174 families) had LOD scores over
0.9 in the 12 cM interval between 93 and 105 cM on
this chromosome, whereas the four smaller collections
(n< 25 families) contributed little evidence to this
signal. Curiously, the six positive family collections
include all ﬁve groups originating from Europe/
Australia, suggesting a possible geographical associa-
tion to the chromosome 4 linkage, although limited
sample size of the US family sets, or chance occurrence
The Prostate
Fig. 2. (Continued )
SNPLinkage Scanof 762 PCFamilies 417
The Prostate
TABLE IV. LODScore SummarySubsets of Families
Chr Pos (cM) LODa Model Region SNP Pos (bp)b
Families with early age at diagnosis (<65, n¼ 405)
1 269 1.95 asm 1q44 rs1148917 243,595,038
3 35 2.05 asm 3p24.3 rs826423 15,316,605
8 59 3.60 dom 8p11.21 rs868586 40,824,008
Families with older age at diagnosis (65, n¼ 357)
4 95 4.50 rec 4q22.1 rs729685 90,654,297
12 113 3.14 dom 12q23.2 rs1544921 100,635,304
13 15 2.23 rec 13q12.13 rs977655 25,202,569
18 43 1.91 rec 18q11.2 rs948384 18,260,958
Families with more aggressive disease (n¼ 348)
1 255 2.11 dom 1q43 rs528011 238,084,930
2 218 2.24 asm 2q35 rs746233 220,092,370
4 149 1.94 dom 4q32.1 rs716428 156,726,319
8 126 3.17 rec 8q24.13 rs2833 124,055,830
8 132 3.17 dom 8q24.21 rs7814955 127,491,272
8 139 3.09 asm 8q24.21 rs766811 130,073,850
12 146 2.23 dom 12q24.31 rs2197777 124,397,172
Families with ﬁve or more affected (n¼ 47)
13 128 2.46 asm 13q34 rs1885688 112,942,237
15 40 2.00 rec 15q14 rs276855 37,318,605
16 48 2.00 rec 16p12.1 rs991911 24,198,554
aHLOD scores listed for dom and rec models.
bhg18 (http://genome.ucsc.edu/).
Fig. 3. a:PlotofLODScores for familieswithaverageageatdiagnosis65.b:ChromosomeswithLODscores1.86infamilieswithaverage
ageatdiagnosis65.
are also possible explanations for this observation. It is
of interest that recent GWAS ﬁndings have led to the
identiﬁcation and conﬁrmation of several SNPs on 4q22
and 4q24, in introns of PDLIM5, and upstream of TET2,
respectively, as being associated with PC risk [18].
Whether or not common risk alleles at these or nearby
loci play a role in the linkage signal observed in the
larger family collections studied here is a question for
further investigation.
Stanford et al. [35] recently reported a SNP-based
linkage scan in which several linkage signals were
reported to coincide with results from this study.
Speciﬁcally, coincident peaks were observed at 15q13–
14 and 2q14–21 in this study and the one reported here,
although the signals were observed in different subsets
of PC families. Evidence of linkage to the long arm of
chromosome 8 (8q22) was observed in the complete set
of 289 Caucasian families.
One of the aims of this study was to replicate
ﬁndings from our earlier MS scan [7]; however few loci
were observed in both studies.While this is disappoint-
ing, it is not surprising given the known genetic
heterogeneity of PC. Indeed, a limitation of our study
is the potentially heterogeneous genetic and environ-
mental inﬂuences arising from a collection of families
from multiple locations across the US, Europe, and
Australia. Over half of the families (65%) studied in this
scan were collected in Europe or Australia, while the
majority of families (79%) studied in our previous MS
scan were collected in the US. Differences in intensity
of PC screening in Europe versus the US may lead to
substantial differences in the distribution of disease
stage at diagnosis (e.g., lower stage due to widespread
PSA testing in the US). While we have attempted to
address someof thesedifferencesby examining speciﬁc
subsets of PC families stratiﬁed by age at diagnosis and
clinical and pathologic variables of the disease, this
may not be sufﬁcient to account for the heterogeneity
that may be introduced by the differences in clinical
practices between the continents.
It should be noted that with respect to comparability
with our previous MS scan, while in general the family
characteristics were quite similar, the families in this
scan had on average fewer members affected with PC
The Prostate
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(2.3 per family compared with 3.5 in the MS scan).
This fact could have implications with respect to the
linkage evidence on 8q24. Smaller numbers of affected
individuals within families could reﬂect a greater
presence of sporadic disease. While little is known
about the role of 8q24 susceptibility variants in familial
PC, there is unequivocal evidence that these risk alleles
are associated with sporadic PC even though the
relative risks associatedwith these risk alleles are small
to modest. It is interesting to note that the Icelandic
families in which the 8q24 locus was originally
identiﬁed through linkage analysis were of similar
average size to the families in this study [22].
The strengths of this study are its large size and
increased genetic information and resolution due to the
use of dense SNP panels for genotyping. While the
wide area of family ascertainment may generate
heterogeneity, the large number of families afforded
by this approach increases power and possibly results
in the identiﬁcation of more robust genetic signals.
Finally, the large number of families increases our
ability to examine potentially more homogeneous
subsets of families while still maintaining reasonable
levels of power.
In summary, in an examination of results fromahigh
resolution SNP scan of 762 families and a previous MS
scan of 1,233 independent PC families, no locus
emerges as an unequivocally strong candidate.
However, our results suggest that a broad region on
proximal 4q, and multiple regions on chromosome 8
are possible candidate regions harboring PC suscept-
ibility loci. In light of evidence from this and previous
studies, further analysis of these regions appears
warranted.
METHODS
Ascertainmentof Families
The ICPCG study populations have been previously
described in detail [36]. Each group within the ICPCG
recruited PC families and 11 ICPCG groups
contributed to this combined genome-wide screen:
ACTANE (Anglo/Canadian/Texan/Australian/Nor-
wegian/European Union Biomed), Centre de
Recherche sur les Pathologies Prostatiques, (CeRePP)
in France, Johns Hopkins University (JHU),
Mayo Clinic, University of Michigan, Northwestern
The Prostate
Fig. 4. a: Plot of LOD Scores for families with more aggressive disease. b: Chromosomes with LOD scores1.86 in families with more
aggressivedisease.
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University, PROGRESS (Prostate Cancer Genetic
Research Study, Fred Hutchinson Cancer Research
Center), University of Tampere in Finland, University
of Ulm in Germany, Karolinska Insititute in Sweden,
andUniversity ofUtah. Therewere 762 PCpedigrees in
this combined analysis. The research protocols and
informed consent procedures were approved by each
group’s institutional review board.
Def|nition of Affected Status and
Classif|cation of Pedigrees
Affected individuals were deﬁned as men diag-
nosed with PC that had been conﬁrmed by either
medical records or death certiﬁcates. Self- or relative-
reported affected men without either medical records
or death certiﬁcate conﬁrmation were considered as
The Prostate
Fig. 4. (Continued )
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having unknown affected status. All men without a
diagnosis of PC were coded as having unknown
affected status, regardless of whether they had under-
gone screening for PC. Hence, all analyses were based
on the sharing of marker genotypes among affected
individuals, with no consideration of the phenotype for
the remaining subjects. Family members not consid-
ered affected nonetheless contributed genotype infor-
mation, when available, to increase the linkage
information content among the affectedmen.Although
such an approach may result in some loss of power, it
provided a uniform approach across all participating
groups, particularly important because screening of
unaffected men varied across groups.
For subset analyses, pedigrees were stratiﬁed
according to the following criteria: (1) average age at
diagnosis within families, contrasting <65 years to
65þ years; (2) families with aggressive disease based
on criteria previously described [37]. Brieﬂy, families
meeting these criteria had three or more affected
individuals with PC with at least one of the following
clinicopathologic characteristics: Gleason score 7 or
higher, TNMstageof T3or T4, pretreatment serumPSA
20 ng/ml, or death from PC before the age of 65. In
these families, other cases not meeting any of the
criteria for aggressive disease were classiﬁed as having
unknown disease status; (3) families having ﬁve or
more affected individuals.
Genotyping
Genome-wide SNP linkage scan genotyping was
performed at the Center for Inherited Disease Research
using Illumina’s HumanLinkage-12 Genotyping Bead-
Chip (http://www.cidr.jhmi.edu/human_snp.html).
These chips assay 6,090 SNP markers, with an average
intermarker distance of 0.58 cM across the genome
and an average marker heterozygosity of 0.43 in
Caucasians.
Statistical Analysis:Linkage-AnalysisMethods
The computer programs Pedcheck (http://watson.
hgen.pitt.edu/register/docs/pedcheck.html) and
PREST (http://galton.uchicago. edu/mcpeek/soft-
ware/prest/) were used for checking whether the
genotypes of individuals within a pedigree are
The Prostate
Fig. 5. a:PlotofLODScores for familieswith5ormoreaffectedmembers.b: ChromosomeswithLODscores1.86 in familieswith five or
more affectedmembers. c: Chromosome 21in families with five ormore affectedmembers.The position of ERG and TMPRSS2, two genes
knowntoundergo commongenomicrearrangementleading togene fusionandactivationofERG[41], isnoted.
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consistent with their speciﬁed relationships. Based on
these analyses, 58 individuals were removed from
further analysis.
Both parametric and nonparametric linkage analy-
ses were performed using Merlin software [38]. The
parametric LOD scores were computed using either a
dominant or a recessive model, as described elsewhere
[5]. LOD scores allowing for linkage heterogeneity
among families (HLOD) were estimated using
HOMOG [39]. Nonparametric LOD scores were calcu-
lated using the Kong and Cox exponential allele
sharing model score (herein referred to as asm) [40].
Marker allele frequencies for each SNPwere estimated
by counting alleles across all genotyped subjects,
ignoring genetic relationships. Multipoint linkage
statistics were calculated at 0.5 cM intervals across the
genome.
We used the r2 option (0.1) of Merlin to remove
SNPs that were in linkage disequilibrium (LD). This is
necessary to reduce the positive bias of strong marker
LD among ﬂanking SNPs on linkage results, and to
reduce the memory and time requirements for large
pedigrees. To further ﬁt pedigree data into thememory
limits of Merlin software, trimming of family members
was conducted.Un-genotyped subjects or subjectswith
missing phenotypes were trimmed. Trimming was
performed on each pedigree to obtain a maximum bit
size of 24.
To facilitate comparison of the results of this SNP
scan with our previous scan using microsatellite (MS)
markers, we aligned the results of these two linkage
scans based on physical map positions (Build 35) of
both the microsatellite markers and SNP markers.
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